This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Wednesday's Winners & Losers: Dendreon

Dendreon (DNDN) said that the FDA agreed to let it hasten clinical testing for its prostate cancer vaccine, Provenge. Dendreon still now expects final results from the trial in the second half of 2009 instead of 2010.

Shares jumped 46 cents, or 9.3%, to $5.39.

Shares of semiconductor equipment maker KLA-Tencor (KLAC) fell $4.13, or 9.9%, to $37.80 after an Oppenheimer analyst cut his rating on the stock to underperform from perform.

The company is facing a decline in its market share and a "downward spiral" in one of its key product lines representing 10% to 15% of total revenue.

Boston Beer (SAM), which makes beer in the Bay State's capital, climbed 26% to $45.16 after reporting fourth-quarter earnings shortly before the close Tuesday. Excluding items, the Samuel Adams brewer's earnings improved to $6.8 million, or 46 cents a share, from $2.5 million, or 17 cents a share, in the year-ago quarter. Analysts polled by Thomson Financial were expecting 35 cents a share.

Shares of hardwood flooring vendor Lumber Liquidators (LL) also jumped, 15.5% to $8.81. The Toano, Va.-based company announced a year-over-year fourth-quarter profit increase of 71% to 12 cents a share, beating the consensus estimate by 2 cents. Revenue increased 24% year over year to $105.5 million. Lumber Liquidators also guided in line for 2008, forecasting EPS between 70 cents and 78 cents and revenue of $475 million to $490 million.

Shares of GPS-based navigation devices maker Garmin (GRMN) added $2.59, or 4.6%, to $58.82 after a favorable article in Barron's Web site said the company's continued strong execution and its position as the market leader in the U.S. will work in its favor.

Elsewhere, Third Wave Technologies (TWTI) surged after the company said its test for high-risk HPV and an HPV genotyping test were successful in a clinical trial. Used with a Pap test, the company's HPV test checks for 14 strains of HPV. The genotyping product checks for HPV types 16 and 18, which cause 70% of cervical cancer cases.

The company, which said it would submit the results to the FDA in April, saw its shares soar $1.95, or 31.5%, to $9.34.

This article was written by a staff member of TheStreet.com.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs